For Q2, we expect to achieve revenues of approximately $97 million. And as Charlie said, we've revised our full year revenue guidance to the higher end of the range between $390 million and $400 million. Operating expenses not including non-cash stock compensation for the quarter were $93.6...
BioCryst Pharmaceuticals stock price target raised to $15 from $10 at J.P. Morgan Mar. 17, 2021 at 7:21 a.m. ET by Tomi Kilgore Breaking BioCryst stock rallies on start of coronavirus drug study Apr. 9, 2020 at 5:52 p.m. ET by Wallace Witkowski S&P 500, Nasdaq close low...